Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families

Clinical Genetics

Volumn 77, Issue 4, 2010, Pages 333-341

  Bartsch, D K ^a   Langer, P ^a   Habbe, N ^a   Matthai E ^a   Chaloupka, B ^a   Sina, M ^a   Hahn, S A ^b   Slater, E P ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

BRCA2; CDKN2A; FAMMM; Melanoma; Pancreatic cancer; PCMS

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR LIKE PROTEIN 11; BRCA2 PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GERMLINE MUTATION; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PEDIGREE ANALYSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; PANCREATIC NEOPLASMS; PEDIGREE; PHENOTYPE; POLYMORPHISM, GENETIC; SKIN NEOPLASMS; YOUNG ADULT;

EID: 77951739522     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01352.x     Document Type: Article

References (46)

1. Ehrenthal D, Haeger L, Griffi T. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987, 59:1661-1664.
2. MacDermott RP, Kramer P. Adenocarcinoma of the pancreas in four siblings. Gastroenterology 1973, 65:137-139.
3. Reimer RR, Fraumeni JF, Ozols RF. Pancreatic cancer in father and son. Lancet 1977, 1:911.
4. Lynch H, Lanspa S, Fitzgibbons RJ. Familial pancreatic cancer (Part 1): genetic pathology review. Nebr Med J 1989, 74:109-112.
5. Bartsch DK, Kress R, Sina-Frey M. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004, 110:902-906.
6. Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003, 103:525-530.
7. Bergman W, Gruis NA, Frants RR. The Dutch FAMMM family material: clinical and genetic data. Cytogenet Cell Genet 1992, 59:161-164.
8. Greene MH, Tucker MA, Clark WH. Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol 1987, 16:792-797.
9. Norris WA. A case of fungoid disease. Edinb Med Surg J 1820, 16:562-565.
10. Lynch H, Krush A. Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J 1968, 99:17-21.
11. Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978, 15:352-356.
12. Lynch HT, Brand RE, Hogg D. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002, 94:84-96.
13. Lynch H, Fusaro R, Kimberling W. Familial atypical multiple mole-melanoma (FAMMM) syndrome: segregation analysis. J Med Genet 1983, 20:342-344.
14. Goldstein A, Fraser M, Struewing J. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995, 333:970-974.
15. Vasen HF, Gruis NA, Frants RR. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000, 87:809-811.
16. Bartsch D, Sina-Frey M, Lang S. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002, 236:730-737.
17. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 1995, 333:975-977.
18. Moskaluk CA, Hruban H, Lietman A. Novel germline p16(INK4) allele (ASP145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. Hum Mutat 1998, 12:70.
19. Borg A, Sandberg T, Nilsson K. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92:1260-1266.
20. Rulyak SJ, Brentnall TA, Lynch HT. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 2003, 98:798-804.
21. Serrano M, Hannon GI, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
22. Stott FJ, Bates S, James MC. The alternative product from the human CDKN2a locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998, 17:5001-5014.
23. Bartsch DK, Sina-Frey M, Ziegler A. Update of familial pancreatic cancer in Germany. Pancreatology 2001, 1:510-516.
24. Rieder H, Sina-Frey M, Ziegler A. German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families. Onkologie 2002, 25:262-266.
25. Gerdes B, Kress R, Rieder H. Familial pancreatic cancer - concept for study of the National Case Collection and early diagnosis program for high risk people. Z Arztl Fortbild Qualitatssich 2002, 96:251-255.
26. Brand RE, Lerch MM, Rubinstein WS. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56:1460-1469.
27. Hahn SA, Greenhalf W, Ellis I. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003, 95:214-221.
28. Bartsch DK, Krysewski K, Sina-Frey M. Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 2006, 5:305-308.
29. Dong X, Wang L, Taniguchi K. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72:270-280.
30. Calin GA, Trapasso F, Shimizu M. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005, 352:1667-1676.
31. Nej K, Bartsch DK, Sina-Frey M. The NOD2 3020insC mutation and the risk of familial pancreatic cancer? Hered Cancer Clin Pract 2004, 2:149-150.
32. Pogue-Geile KL, Chen R, Bronner MP. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3:e516.
33. Cybulski C, Huzarski T, Gorski B. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004, 64:2677-2679.
34. Kurzawski G, Suchy J, Kladny J. The NOD2 3020C mutation and the risk of colorectal cancer. Cancer Res 2004, 64:1604-1606.
35. Bergman W, Watson P, de Jong J. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990, 61:932- 936.
36. Ghiorzo P, Gargiulo S, Nasti S. Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. J Clin Oncol 2007, 25:5336-5337.
37. Vogelstein B, Kinzler KW. The genetic basis of human cancer 1998, New York, McGraw-Hill
38. Gruis N, van der Velden P, Sandkuijl L. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995, 10:351-353.
39. Gruis NA, Sandkuijl LA, van der Velden PA. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995, 5:169-177.
40. Monnerat C, Chompret A, Kannengiesser C. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 2007, 6:453-461.
41. Hahn SA, Schmiegel WH. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 1998, 59:493-501.
42. Goldstein A, Chan M, Harland M. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007, 44:99-106.
43. Murphy KM, Brune KA, Griffin C. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-3793.
44. Wu K, Hinson SR, Ohashi A. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005, 65:417-426.
45. Martin ST, Matsubayashi H, Rogers CD. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 2005, 24:3652-3656.
46. Huzarski T, Lener M, Domatala W. The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Res Treat 2005, 89:91-93.